Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Current Oncology (Toronto, Ont.)|October 22, 2021
Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy DatabaseHeidi A I Grosjean, Samantha Dolter, Daniel E Meyers, et al.
Clinical Lung Cancer|February 11, 2023
Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint BlockadeVishal Navani, Daniel E Meyers, Yibing Ruan, et al.
Gastro Hep Advances|October 27, 2025
Recent Abdominal Surgery as a Risk Factor for Unfavorable Immune-Mediated Colitis OutcomesRohan Ahuja, Malek Shatila, Jay Shah, et al.
Current Oncology (Toronto, Ont.)|October 27, 2022
Prevalence, Treatment Patterns, and Outcomes of Individuals with <i>EGFR</i> Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion <i>EGFR</i> Mutation CarriersDylan E O'Sullivan, Tamer N Jarada, Amman Yusuf, et al.
The Lancet. Oncology|May 11, 2020
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trialCatherine A Shu, Justin F Gainor, Mark M Awad, et al.
The Lancet. Oncology|May 3, 2025
Antimicrobial resistance in patients with haematological malignancies: a scoping reviewYa Haddy Sallah, Vanessa F Bratti, Bahar Rafinejad-Farahani, et al.
Cancer Research Communications|April 19, 2026
Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung CancerMichael Conroy, Jaime Wehr, Vivian V Altiery De Jesus, et al.
Annals of Gastroenterology|March 23, 2026
Efficacy of current therapeutic strategies for immune checkpoint inhibitor-related esophagitisCarolina Colli Cruz, Maria Julia M N Santos, Sharada Wali, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2021
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trialsChun L Gan, Igor Stukalin, Daniel E Meyers, et al.
European Journal of Gastroenterology & Hepatology|January 12, 2026
Risk factors and clinical course of inflammatory bowel disease in patients receiving cancer therapyCristina Natha, Carolina Colli Cruz, Varun Vemulapalli, et al.
Pageof 4